NEWS & EVENTS
The Department Pathology and Michigan Medicine Laboratories is pleased to announce and welcome Dr. Liron Pantanowitz, our new A. James French Professor and Director of Anatomic Pathology.
NOW AVAILABLE: NGS Myeloid Panel! MLabs is excited to announce the addition of our new NGS Myeloid
Panel: For any myeloid or suspected myeloid neoplasm.
Featured Test (NEW)
Myeloid NGS Panel
This test is intended for the molecular evaluation of myeloid neoplasms including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemias (AML), mastocytosis and myeloid neoplasms with eosinophilia and gene rearrangement.
NGS Solid Tumor Panel
Molecular testing of solid tumor neoplasms - particularly advanced-stage cancer. This DNA and RNA based, NGS test targets 50 actionable genes (35 mutations, 19 amplifications, 21 - fusions). Requires <1mm2 of tissue (as little as 100 tumor cells) and a low 3% QNS rate.
Erdafitinib (Balversa™) is an FGFR-inhibitor that is FDA-approved for the treatment of metastatic urothelial cancers harboring susceptible mutations or translocations involving FGFR2 or FGFR3.
NR4A3 (9q22-9q31) Rearrangement (FISH)
NR4A3 encodes an orphan nuclear receptor. Rearrangements of NR4A3 occur in more than 80% of extraskeletal myxoid chondrosarcoma (EMC) as well as in salivary acinic cell carcinoma (AciCC), driving tumorigenesis.
NEW TREATMENT OPTION FOR METASTATIC BREAST CANCER
MLabs offers NGS Solid Tumor Panel and Single gene test to detect PIK3CA for FDA approved therapy alpelisib (Piqray®).
TFE3 Rearrangement (FISH)
Detecting rearrangements involving the TFE3 gene region (Xp11.2) via fluorescence in situ hybridization (FISH) to qualitatively assess for the presence of TFE3 translocations that are associated with certain subtypes of renal cell carcinoma. Testing for TFE3 gene rearrangement may aid in the diagnosis and classification of renal tumors.